Literature DB >> 19172229

The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines.

Brigette B Y Ma1, Fion Sung, Qian Tao, Fan Fong Poon, Vivian W Lui, Winnie Yeo, Stephen L Chan, Anthony T C Chan.   

Abstract

The activity of the histone deacetylase inhibitor PXD101 was investigated in three hepatocellular carcinoma (HCC) cell lines. PXD101 was found to inhibit cell growth at a dose-dependent manner and induce histone acetylation in PLC/PRF/5, Hep3B and HepG2 cells. In PLC/PRF/5 and Hep3B cells which express hepatitis B-related genes (HBx, HBc and HBc), treatment with PXD101 resulted in apoptosis without a significant effect on viral gene expression. Exposure to PXD101 for up to 48 h had varying effects on the expression of 12 cellular genes with tumor suppressor functions, including p21, SOCS1, CMTM5, RASAL1, DLEC1, SFRP (-1, -2, -4 and -5), ADAMTS (-8 and -9). This study provided the basis for a phase II clinical trial of PXD101 in inoperable hepatitis-B associated HCC.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19172229     DOI： 10.1007/s10637-009-9219-7

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  35 in total

1.  Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9.

Authors:  P H Y Lo; A C C Leung; C Y C Kwok; W S Y Cheung; J M Y Ko; L C Yang; S Law; L D Wang; J Li; E J Stanbridge; G Srivastava; J C O Tang; S W Tsao; M L Lung
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

2.  Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas.

Authors:  T Matsumura; R Makino; K Mitamura
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

3.  Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein.

Authors:  In Young Park; Bo Hwa Sohn; Eunsil Yu; Dong Jin Suh; Young-Hwa Chung; Je-Ho Lee; Stefan J Surzycki; Young Ik Lee
Journal:  Gastroenterology       Date:  2007-01-25       Impact factor: 22.682

4.  The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.

Authors:  T J Seng; J S W Low; H Li; Y Cui; H K Goh; M L Y Wong; G Srivastava; D Sidransky; J Califano; R D M Steenbergen; S Y Rha; J Tan; W-S Hsieh; R F Ambinder; X Lin; A T C Chan; Q Tao
Journal:  Oncogene       Date:  2006-07-24       Impact factor: 9.867

5.  Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells.

Authors:  Tetsuhiro Chiba; Osamu Yokosuka; Makoto Arai; Motohisa Tada; Kenichi Fukai; Fumio Imazeki; Masaki Kato; Naohiko Seki; Hiromitsu Saisho
Journal:  J Hepatol       Date:  2004-09       Impact factor: 25.083

6.  The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle.

Authors:  Guo-Hua Qiu; Manuel Salto-Tellez; James A Ross; Winnie Yeo; Yan Cui; Nicholas Wheelhouse; George G Chen; David Harrison; Paul Lai; Qian Tao; Shing Chuan Hooi
Journal:  J Hepatol       Date:  2007-12-31       Impact factor: 25.083

7.  CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines.

Authors:  Luning Shao; Yan Cui; Hongyu Li; Yanan Liu; Hongshan Zhao; Yu Wang; Yingmei Zhang; Ka Man Ng; Wenling Han; Dalong Ma; Qian Tao
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

8.  Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers.

Authors:  Hongchuan Jin; Xian Wang; Jianming Ying; Ada H Y Wong; Yan Cui; Gopesh Srivastava; Zhong-Ying Shen; En-Min Li; Qian Zhang; Jie Jin; Sabine Kupzig; Anthony T C Chan; Peter J Cullen; Qian Tao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-18       Impact factor: 11.205

9.  Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation.

Authors:  Luke O Dannenberg; Howard J Edenberg
Journal:  BMC Genomics       Date:  2006-07-19       Impact factor: 3.969

10.  Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.

Authors:  Jane A Plumb; Paul W Finn; Robert J Williams; Morwenna J Bandara; M Rosario Romero; Claire J Watkins; Nicholas B La Thangue; Robert Brown
Journal:  Mol Cancer Ther       Date:  2003-08       Impact factor: 6.261
View more
  22 in total

Review 1.  Management of hepatocellular carcinoma: beyond sorafenib.

Authors:  Stephen L Chan; Tony Mok; Brigette B Y Ma
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

Review 2.  Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma.

Authors:  Bhavna Rani; Yuan Cao; Andrea Malfettone; Ciprian Tomuleasa; Isabel Fabregat; Gianluigi Giannelli
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 3.  Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.

Authors:  Stephen L Chan; Winnie Yeo
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

4.  Belinostat: first global approval.

Authors:  Raewyn M Poole
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 5.  Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.

Authors:  Jiahuai Tan; Shundong Cang; Yuehua Ma; Richard L Petrillo; Delong Liu
Journal:  J Hematol Oncol       Date:  2010-02-04       Impact factor: 17.388

Review 6.  Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives.

Authors:  Li Ma; Mei-Sze Chua; Ourania Andrisani; Samuel So
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

7.  Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients.

Authors:  Hidefumi Sasaki; Yu Hikosaka; Osamu Kawano; Satoru Moriyama; Motoki Yano; Yoshitaka Fujii
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

8.  Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.

Authors:  Winnie Yeo; Hyun C Chung; Stephen L Chan; Ling Z Wang; Robert Lim; Joel Picus; Michael Boyer; Frankie K F Mo; Jane Koh; Sun Y Rha; Edwin P Hui; Hei C Jeung; Jae K Roh; Simon C H Yu; Ka F To; Qian Tao; Brigette B Ma; Anthony W H Chan; Joanna H M Tong; Charles Erlichman; Anthony T C Chan; Boon C Goh
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

9.  Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.

Authors:  Dmitriy I Dovzhanskiy; Stefanie M Arnold; Thilo Hackert; Ina Oehme; Olaf Witt; Klaus Felix; Nathalia Giese; Jens Werner
Journal:  BMC Cancer       Date:  2012-06-08       Impact factor: 4.430

10.  Targeted therapies in the treatment of advanced hepatocellular carcinoma.

Authors:  Zhengyu Wei; Cataldo Doria; Yuan Liu
Journal:  Clin Med Insights Oncol       Date:  2013-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.